|
WO2017165859A1
|
|
Modified viral capsid proteins
|
|
WO2017100782A1
|
|
Systems and methods for optimized patient specific tissue engineering vascular grafts
|
|
WO2017079505A1
|
|
Rnase7 for treatment of bacterial infection
|
|
WO2017066719A2
|
|
Hu specific interfering agents
|
|
WO2017058938A1
|
|
Methods for detecting hepatic fibrosis and responsiveness to therapy
|
|
WO2017058735A1
|
|
Compositions and methods for inhibiting the growth of neisseria gonorrhoeae
|
|
WO2017011588A1
|
|
Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
|
|
WO2016205641A2
|
|
Respiratory syncytial virus having cleavage-resistant g protein and related materials and methods
|
|
WO2016161413A1
|
|
Urinary tract infection biomarkers
|
|
WO2016134378A1
|
|
Live attenuated vaccines for pneumoviruses and related methods and materials
|
|
CA2965988A1
|
|
Parallel-processing systems and methods for highly scalable analysis of biological sequence data
|
|
US2017173113A1
|
|
Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes
|
